ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.27
-0.14 (-2.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.41
Open5.40
Bid5.05 x 900
Ask9.20 x 900
Day's Range5.24 - 5.50
52 Week Range4.99 - 16.70
Volume332,281
Avg. Volume256,077
Market Cap144.875M
Beta (3Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-1.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.29
Trade prices are not sourced from all markets
  • Here’s What Hedge Funds Think About Aldeyra Therapeutics Inc (ALDX)
    Insider Monkey17 days ago

    Here’s What Hedge Funds Think About Aldeyra Therapeutics Inc (ALDX)

    Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]

  • Benzinga27 days ago

    No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

    Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX ), a thinly traded micro-cap biotech, plummeted Tuesday morning. What Happened Aldeyra, which focuses on therapies for immune-mediated diseases, reported ...

  • MarketWatch27 days ago

    Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

    Aldeyra Therapeutics Inc. shares were down 29% in premarket trade Tuesday, after the company said a trial of a treatment for uveitis, or inflammation of the eye, failed to meet its main goals. The company said the trial called Solace failed to achieve statistical significance in primary or secondary endpoints, "due to high rates of disease resolution in vehicle-treated patients, but activity of reproxalap was consistently greater than that of vehicle." Aldeyra Chief Executive Todd Brady said the results "confirm the potential of reproxalap to treat ocular inflammation, and further validate the novel mechanism of action of reproxalap, which demonstrated highly statistically significant immune-modulating activity in the Phase 3 ALLEVIATE Trial and Phase 2b Dry Eye Disease trial." The company will continue to prioritize programs in eye treatments, he said. The company will host a conference call at 8.00 a.m. Eastern. Shares have fallen 14.6% in 2019, while the S&P 500 has gained 17.5%.

  • Business Wire27 days ago

    Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis

    “The results of the SOLACE Trial confirm the potential of reproxalap to treat ocular inflammation, and further validate the novel mechanism of action of reproxalap, which demonstrated highly statistically significant immune-modulating activity in the Phase 3 ALLEVIATE Trial and Phase 2b Dry Eye Disease trial,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. Reproxalap ophthalmic solution, in various concentrations, has now been administered to over 800 patients in nine clinical trials for ocular inflammation.

  • Business Wire28 days ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis

    Aldeyra Therapeutics, Inc. , a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference call on Tuesday, June 25, 2019 at 8:00 a.m.

  • PR Newswire2 months ago

    Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference

    LEXINGTON, Mass. , May 30, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT

    Q1 2019 Aldeyra Therapeutics Inc Earnings Call

  • Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript

    ALDX earnings call for the period ending .

  • PR Newswire2 months ago

    Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update

    - Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis - Initiated Adaptive Phase 3 RENEW Trial in Dry Eye Disease - Last Patient Dosed in Phase 3 SOLACE Trial in Noninfectious ...

  • PR Newswire3 months ago

    Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019

    LEXINGTON, Mass. , May 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • PR Newswire3 months ago

    Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial

    LEXINGTON, Mass., April 30, 2019 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed dosing in the SOLACE Phase 3 clinical trial of topical ocular reproxalap in patients with noninfectious anterior uveitis. "We look forward to announcing the results of the SOLACE trial, our second Phase 3 clinical trial to complete this year," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Noninfectious anterior uveitis is a rare but severe inflammatory ocular disease characterized by pain, photophobia, and, in some cases, vision loss.

  • PR Newswire3 months ago

    Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Reproxalap is a novel immune-modulating RASP (Reactive Aldehyde Species) inhibitor in late-stage development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Results from a Phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. The RENEW adaptive Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease initiated on April 1, 2019.

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease

    LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the RENEW Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease. The RENEW Trial is a two-part, multi-center, randomized, double-masked, parallel-group, vehicle-controlled, adaptive Phase 3 clinical trial evaluating the efficacy of reproxalap ophthalmic solution (0.25%) vs. vehicle in 400 patients with moderate-to-severe dry eye disease.  Results from the first part of the trial will confirm the dosing regimen and sample size for the second part.  The co-primary endpoints of the trial will be ocular dryness and fluorescein nasal region ocular staining in pre-specified moderate to severe patient subsets analyzed over twelve weeks of therapy using Mixed effects Model Repeated Measures (MMRM).

  • Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
    Zacks4 months ago

    Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge

    Aldeyra (ALDX) announced positive top-line data from a phase III study on pipeline product, reproxalap topical ophthalmic solution in patients with allergic conjunctivitis.

  • TheStreet.com4 months ago

    Future Brightens for 2 Small Biotech Stocks

    The biotech sector got off to a quick start in 2019 but largely has been range-bound here in March -- not that things have not been exciting. Small-cap concerns in the sector also have become more volatile in the last few trading sessions.

  • Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
    Motley Fool4 months ago

    Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

    The small-cap pharma announced positive results from a phase 3 trial.

  • Aldeyra stock jumps 50 percent after eye allergy trial success
    American City Business Journals4 months ago

    Aldeyra stock jumps 50 percent after eye allergy trial success

    Quiet local biotech Aldeyra Therapeutics made some noise Tuesday, reporting that its first treatment for eye allergies succeeded in a late-stage trial.

  • Reuters4 months ago

    Aldeyra's eye drug meets main goal in late-stage study, shares surge

    The study tested two doses of the drug in 318 patients with seasonal allergic conjunctivitis, an allergic reaction to substances such as pollen or spores causing eye inflammation. Both concentrations of reproxalap exhibited an anti-inflammatory profile distinct from standard-of-care and support a different mechanism of action for the treatment of allergic conjunctivitis, the company said. The results suggest the potential of reproxalap being used to complement existing therapy, Aldeyra Chief Medical Officer David Clark said in a statement.

  • Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?
    Simply Wall St.4 months ago

    Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It's been a soft week for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)Read More...

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap. "We are thrilled to announce positive results from ALLEVIATE, our first completed Phase 3 clinical trial," commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra.

  • PR Newswire4 months ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis

    LEXINGTON, Mass. , March 25, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...

  • Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock
    Zacks4 months ago

    Options Traders Expect Huge Moves in Aldeyra (ALDX) Stock

    Aldeyra (ALDX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT

    Q4 2018 Aldeyra Therapeutics Inc Earnings Call